MacroGenics (MGNX) and Incyte (INCY) enter global collaboration and license agreement

** charts after announcement **

** charts before  announcement **

  

MacroGenics and Incyte (INCY) enter global collaboration and license agreement for MacroGenics' MGA012; MGNX will recieve an upfront payment of $150 mln 
Upon closing, Incyte will pay MacroGenics an upfront payment of $150 million. Incyte will receive worldwide rights to develop and commercialize MGA012 in all indications.
Per the terms of the collaboration, MacroGenics will also be eligible to receive up to $420 million in potential development and regulatory milestones, and up to $330 million in potential commercial milestones. If MGA012 is approved and commercialized, MacroGenics would be eligible to receive royalties, tiered from 15 percent to 24 percent, on future sales of MGA012 by Incyte.